Dr. Noah E. Canvasser, MD

Dr. Canvasser practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Canvasser's NPI, 1578882072, was assigned on May 24, 2010. Dr. Canvasser graduated from UC Irvine School of Medicine in 2010. Dr. Canvasser holds California license A148672.

Dr. Canvasser's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Canvasser's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Canvasser is also affiliated with Oroville Hospital. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Canvasser to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Canvasser practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Canvasser's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Canvasser is board certified in urology by the American Board of Urology. Dmand AI has Dr. Canvasser's licenses on file in 3 states: California, Texas and Michigan.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease, kidney stones and prostate cancer among the conditions Dr. Canvasser treats.

CMS data shows 1,475 Medicare services from Dr. Canvasser across 22 procedure codes in 2024, for 698 Medicare patients. Medicare paid $179,303 for them.

CMS counts 698 Medicare patients who saw Dr. Canvasser in 2024. The largest group is 65 to 74, with 315 patients. 74% of them have high cholesterol, and 71% have high blood pressure. 19% are also on Medicaid. Their average risk score is 1.45, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Canvasser's median patient age at 64, with 32% women.

In 2024, Dr. Canvasser wrote 1,313 Medicare Part D claims for 403 patients. 95% of them were for generic drugs. CMS names the drug for 1,195 of them, across 15 drugs with 11 or more claims each, at $208,138 in total drug cost. In 2023, CMS named 1,024 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Canvasser for performance year 2024, reported as part of a group. Dr. Canvasser accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Canvasser as offering telehealth. CMS counts 120 procedures of prostate resection by Dr. Canvasser, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 28 papers to Dr. Canvasser, published from 2010 to 2022. 2017 was the busiest year, with 8. The most frequent topics are Kidney Neoplasms, Carcinoma, Renal Cell and Catheter Ablation. Dr. Canvasser has published most often in J Endourol. Dr. Canvasser's most frequent co-authors are Jeffrey Anthony Cadeddu, MD, Igor Sorokin, MD and Seth K. Bechis, MD.

CMS Open Payments shows 229 general payments to Dr. Canvasser from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 53% of the total. Boston Scientific Corporation paid the most, $131,349.

Dr. Canvasser graduated from UC Irvine School of Medicine in 2010.

Dr. Canvasser is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.